Actively Recruiting
Modulation of Gut Microbiota Composition and Gut Permeability Profiles by Multispecies Synbiotic Supplementation in Hemodialysis Patients
Led by Tungs' Taichung Metroharbour Hospital · Updated on 2026-06-03
30
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Chronic kidney disease (CKD) patients on maintenance hemodialysis often experience significant changes in their gut bacteria, leading to harmful imbalances and increased gut leakiness. This allows toxins from the gut to enter the bloodstream, contributing to inflammation, heart disease risk, and faster CKD progression. Researchers are studying how a multispecies synbiotic supplement might improve these gut issues and reduce harmful toxins in hemodialysis patients. Participants will take a multispecies synbiotic supplement called Renobiome, containing 30 billion colony-forming units per capsule from several Lactobacillus strains and Lactococcus lactis. The supplement is taken twice daily for 12 weeks, with or without food. The study includes baseline tests of blood, urine, and stool samples, followed by monitoring of symptoms and side effects at 4 weeks and repeat testing at 12 weeks. During the trial, participants will have fasting blood samples collected and analyzed for uremic toxins and gut permeability markers. Stool samples will be examined to assess changes in gut bacteria. Adherence to the supplement will be tracked, and any adverse events will be recorded. The main outcomes measured are changes in fecal microbiome composition and serum levels of uremic toxins and gut permeability markers over one year.
CONDITIONS
Brief Title
Modulation of Gut Microbiota Composition and Gut Permeability Profiles by Multispecies Synbiotic Supplementation in Hemodialysis Patients
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults aged 18 years or older
- Receiving maintenance hemodialysis for at least 3 months
You will not qualify if you...
- Use of probiotic supplements within the last month
- Hospitalization within the past month for acute infections or CKD-related complications
- History of major intestinal surgeries such as gastrectomy or cholecystectomy (appendectomy allowed)
- Presence of viral hepatitis, liver cirrhosis, active malignancy, advanced congestive heart failure, or thyroid disorders
- Use of antibiotics or immunosuppressive therapy within the preceding three months
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 12 weeks
Participants take a multispecies synbiotic supplement twice daily for 12 weeks to assess its effects on gut microbiota and gut permeability.
2 visits (at 4 weeks and 12 weeks)
Trial Site Locations
Total: 1 location
1
Tungs' Taichung Metroharbour Hospital
Taichung, Wuqi District, Taiwan, 435
Actively Recruiting
Research Team
P
Paik Seong Lim, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here